CD4 and melanoma: Several recent studies, focusing on circulating CD4+ T cells, found that increases in central memory CD4+ T cells (CD27+, FAS−, CD45RA−, and CCR7+) (58), and IL-9-producing CD4+ T helper (Th9) cells (59), correlated with good clinical responses of melanoma patients to anti-PD-1 therapy.